Location · Cromwell, CT
Clinical trials in Cromwell, CT
10 recruiting studies have a site in Cromwell, and 0 of them accept healthy volunteers.
10 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 2
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
Oruka Therapeutics, Inc.
- Location
- Cromwell, CT + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
Seaport Therapeutics
- Location
- Cromwell, CT + 26 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Cromwell, CT + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Cromwell, CT + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa
Oruka Therapeutics, Inc.
- Location
- Cromwell, CT + 13 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design
Axsome Therapeutics, Inc.
- Location
- Cromwell, CT + 48 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol
Axsome Therapeutics, Inc.
- Location
- Cromwell, CT + 35 other US sites
- Eligibility basics
- Ages 18–55
- RecruitingPhase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Cromwell, CT + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
AbbVie
- Location
- Cromwell, CT + 46 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics, Inc.
- Location
- Cromwell, CT + 31 other US sites
- Eligibility basics
- Ages 18–65